Top 5 angioedema stories of 2025
Most-read stories focused on HAE attacks, treatments
Written by |
Throughout 2025, the team at Angioedema News brought readers the latest updates on research, treatments, clinical trials, and real-world experiences related to angioedema. From progress in gene-editing approaches to insights into how patients manage swelling attacks, our goal has been to support people living with this rare condition through clear and timely reporting.
Below are the five most-read articles of last year. We look forward to continuing to be a trusted source of news and information for the angioedema community in the years to come.
No. 5 – Delayed on-demand treatment for HAE tied to worse swelling attacks
On-demand treatment for hereditary angioedema (HAE) is recommended as soon as symptoms of a swelling attack begin. But a survey study found that many people delay starting it, mostly due to uncertainty about whether early symptoms are truly an attack, believing the swelling will remain mild, or feeling anxious about using on-demand medication. These delays were linked to attacks that lasted longer, became more severe, and were more likely to spread to other areas of the body. The findings underscore the need for improved treatment options, clearer guidance, and efforts to eliminate barriers that hinder the timely use of on-demand medications.
No. 4 – 1st patient dosed in Phase 3 trial of one-time gene therapy for HAE
The first patient was dosed in a Phase 3 trial to test NTLA-2002, an investigational gene-editing therapy for HAE being developed by Intellia Therapeutics. Designed as a one-time treatment, the therapy aims to prevent swelling attacks by lowering the activity of an enzyme that’s overactive in HAE and affects levels of bradykinin, a signaling molecule that drives these episodes. Study participants will receive either a single infusion of NTLA-2002 or a placebo to evaluate whether the therapy can safely reduce the number of attacks over about six months. The trial is expected to conclude in 2027.
No. 3 – Real-world study shows Takhzyro helps prevent HAE swelling attacks
Takhzyro (lanadelumab), an approved therapy for preventing HAE swelling attacks, was found to be highly effective in reducing these episodes among patients in clinical settings. An analysis of real-world data revealed that most participants saw sharp drops in their monthly attack rates, with many experiencing long periods completely free of swelling episodes. The findings reinforce results seen in clinical trials and support Takhzyro as a long-term preventive treatment for people with HAE.
No. 2 – Intellia to submit NTLA-2002 for FDA review in 2026
Intellia Therapeutics announced plans to seek FDA approval for NTLA-2002, its investigational one-time gene-editing therapy for HAE, in the second half of 2026. The therapy is designed to reduce HAE swelling attacks by lowering the activity of an enzyme that helps regulate bradykinin, a signaling molecule that triggers these episodes. Earlier clinical data showed that most patients were free from swelling attacks in the months after receiving NTLA-2002, with some remaining attack-free for more than a year. NTLA-2002 is now being tested in a Phase 3 trial, and results from this study are expected to support Intellia’s planned submission to the FDA.
No. 1 – People on preventive HAE treatment still struggle with managing attacks
A U.S. survey study found that people with HAE who were on long-term preventive therapy reported many of the same struggles managing and recovering from acute swelling attacks as those using only on-demand treatment. Anxiety about using on-demand medication was common in both groups, and similar proportions of respondents delayed or did not treat attacks because they believed symptoms were not severe enough, lacked access to timely refills, or did not have their medication with them. The findings point to limitations in current on-demand treatments and highlight the need for better education, clearer communication, and further research to address barriers that continue to affect how people manage their HAE attacks.
We hope that these stories, along with all our reporting at Angioedema News, provided helpful information to the Angioedema community throughout 2025. We look forward to continuing to bring you important updates in the year ahead, and we wish all our readers a happy and healthy 2026!
